$CADL

H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.

Candel Therapeutics (CADL) granted stock options to 4 new employees, totaling 85,900 shares at $10.44 per share. The options vest over 4 years, subject to continued service. The grants were made under Nasdaq Rule 5635(c)(4) and the Company's 2025 Inducement Plan. Candel is a clinical-stage biopharmaceutical company focused on cancer immunotherapies.

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

Candel Therapeutics (CADL) presented data at ASTRO 2026 showing aglatimagene besadenovec significantly increased immune response in prostate cancer patients over two years. The phase 3 trial showed 80% of aglatimagene patients had negative biopsies vs. 63% of controls. The company plans to submit a BLA based on these results.

Candel Therapeutics (CADL) shares rose 9.3% premarket after BofA Securities upgraded the stock to Buy and raised the price target to $18.00 from $12.00, citing positive outlook for the biotech sector and key catalysts.

U.S. stock futures rose overnight after the Federal Reserve's 25 basis point rate hike, with Dow, S&P 500, and Nasdaq futures up 0.62%, 0.56%, and 0.57% respectively. The Fed's target rate now ranges from 3.75% to 4.00%. SpaceX (SPCX) shares climbed over 5% on Morgan Stanley's positive rating, while Fluence Energy (FLNC) dropped 15% after cutting fiscal 2026 guidance. Snap (SNAP) gained 2% after unveiling new AI products.

Tak Paul Peter (Chief Executive Officer) sold 280,245 shares of Candel Therapeutics, Inc. (CADL) at an average of $11.28 ($10.46–$11.50, $3.16M total) across 2 trades over 2026-09-10 to 2026-09-11 under a Rule 10b5-1 trading plan.

Candel Therapeutics, Inc. (CADL) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors • Regulatory and quality expertise strengthens Board as Candel advances toward planned Biologics License Application (BLA) submission and potential commercial readiness NEEDHAM, Mass.,

Candel Therapeutics (CADL) stock surged over 190% in six months due to clinical progress. CAN-2409 showed 50% 24-month survival in NSCLC and 39% improvement in prostate cancer survival. CAN-3110 is in Phase 1b for glioblastoma. CADL partnered with EVERSANA and plans a BLA filing for CAN-2409 in Q4 2026.

NeoGenomics (NEO), BlossomHill Therapeutics (BLSM), Revolution Medicines (RVMD), Oramed Pharmaceuticals (ORMP), and Candel Therapeutics (CADL) reached 52-week highs on August 27, 2026. NEO reported Q2 revenue growth of 11% and a profit turnaround. BLSM began trading on Nasdaq and received FDA Fast Track designation. RVMD's lead drug, Rasonque, was FDA-approved. ORMP's net income increased significantly. CADL reported a higher net loss but plans a BLA filing for its lead drug.